Anika Therapeutics (ANIK) Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Current Assets data on file, last reported at $93.6 million in Q1 2026.

• On a quarterly basis, Current Assets fell 8.73% year-over-year to $93.6 million in Q1 2026; TTM through Mar 2026 was $93.6 million, a 8.73% decrease from a year earlier, with the FY2025 full-year figure at $103.4 million, down 9.06% from the prior year.
• Current Assets for Q1 2026 stood at $93.6 million, down from $103.4 million in the prior quarter.
• Over the last five years, Current Assets for ANIK reached as high as $169.5 million in Q4 2022 and fell as low as $93.6 million in Q1 2026.
• Historically, Current Assets has averaged $139.2 million across 5 years, with a median of $155.0 million in 2024.
• Across the five-year window, Current Assets advanced 1.84% in 2024 and plunged 35.92% in 2025, its largest moves.
• Year by year, Current Assets stood at $169.5 million in 2022, then slipped by 3.68% to $163.3 million in 2023, then sank by 30.41% to $113.7 million in 2024, then retreated by 9.06% to $103.4 million in 2025, then decreased by 9.48% to $93.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $93.6 million in Q1 2026, $103.4 million in Q4 2025, and $101.6 million in Q3 2025.